Proximagen Limited   Report issue

For profit Phase 2
Founded: London United Kingdom (2003)
Status: Acquired by Upsher-Smith Laboratories (2012)

Organization Overview

First Clinical Trial
2013
NCT01945346
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

prx167700 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1